Dr Reddy’s Laboratories Appoints Sanjay Sharma as its CHRO
Dr Reddy’s Laboratories has named Sanjay Sharma as its new Chief Human Resources Officer (CHRO), starting on 1 December 2025, as part of a scheduled leadership change at the pharmaceutical giant.
Sharma, presently the Global Head of Operations and Senior Management Personnel, is set to assume the HR responsibilities after Archana Bhaskar’s resignation, whose term ends on 30 November 2025, as per reports.
The firm revealed the leadership shift after trading ended on Friday. Dr. Reddy’s announced that Sharma will assume additional responsibilities focused on enhancing the organization's talent strategy and workforce skills as it speeds up digital transformation and operational expansion.
Sharma, a veteran leader in Dr Reddy’s worldwide operations, offers extensive expertise in overseeing substantial business processes, supply chains, and organizational effectiveness. His advancement to the CHRO position highlights the company's focus on aligning human capital priorities with its wider business and innovation strategies.
Also Read: SCO Summit 2025: Outcomes of Modi-Xi Meeting
The appointment further highlights Dr. Reddy’s approach of utilizing internal leadership to ensure consistency and cohesion in its worldwide markets. Industry analysts observe that internal changes of this nature have become more prevalent in major pharmaceutical firms, especially when human resource strategy is deeply connected to operational effectiveness and cultural change.
Also Read: A Brief History of India's Transformation Under PM Narendra Modi
The announcement of leadership happened simultaneously with the release of Dr Reddy's results for the second quarter. The firm announced a 7 percent increase in consolidated net profit to Rs.1,347 crore, rising from Rs.1,255 crore the previous year, as per reports.
Reflecting on the results, GV Prasad, Co-Chairman and Managing Director, stated that growth was fueled by branded markets and the NRT portfolio, noting that the company continued to emphasize enhancing its core business and progressing its product pipeline.
Also Read: 5 Latest CHRO Appointments in Global Corporations
Dr Reddy’s stock finished 0.32 percent up at Rs.1,284 on the BSE prior to the announcements. The transition in leadership and consistent quarterly results occur as the company persists in investing in research, digital advancements, and global workforce enhancement — domains where Sharma is anticipated to be crucial in directing the next growth phase.